Tiina Vesterinen

Tiina Vesterinen

Auto-generated profile, based on publicly available information

Tiina Vesterinen

HUS Diagnostic Centre, Department of Pathology, Helsinki University Hospital and University of Helsinki , Helsinki

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2011 in The EMBO Journal
Verified
Journal Article
Closed access
BSBiswajyoti Sahu
Biswajyoti Sahu
MLMarko Laakso
Marko Laakso
KOKristian Ovaska
Kristian Ovaska
TMTuomas K. Mirtti
Tuomas K. Mirtti
JLJohan Lundin
Johan Lundin
OJOlli A Jänne
Olli A Jänne

28 November 2011 in Oncogene
Verified
Journal Article
Closed access
MBM Björkman
M Björkman
PÖP Östling
P Östling
VHV Härmä
V Härmä
JVJ Virtanen
J Virtanen
JMJ-P Mpindi
J-P Mpindi
Matthias NeesMatthias Nees
Matthias Nees

6 November 2021 in APMIS
Verified
Journal Article
Open access
PDF file
TVTiina Vesterinen
Tiina Vesterinen
JSJenni Säilä
Jenni Säilä
SBSami Blom
Sami Blom
MPMirkka Pennanen
Mirkka Pennanen
HLHelena Leijon
Helena Leijon
JAJohanna Arola
Johanna Arola
The Ki‐67 proliferation index (PI) is a prognostic factor in neuroendocrine tumors (NETs) and defines tumor grade. Analysis of Ki‐67 PI requires calculation of Ki‐67‐positive and Ki‐67‐negative tumor cells, which is highly subjective. To overcome this, we developed a deep learning‐based Ki‐67 PI algorithm (KAI) that objectively calculates Ki‐67 PI. Our study material consisted of NETs divided into training (n = 39), testing (n = 124), and validation (n = 60) series. All slides were digitized and processed in the Aiforia® Create (Aiforia Technologies, Helsinki, Finland) platform. The ICC between the pathologists and the KAI was 0.89. In 46% of the tumors, the Ki‐67 PIs calculated by the pathologists and the KAI were the same. In 12% of the tumors, the Ki‐67 PI calculated by the KAI was 1% lower and in 42% of the tumors on average 3% higher. The DL‐based Ki‐67 PI algorithm yields results similar to human observers. While the algorithm cannot replace the pathologist, it can assist in the laborious Ki‐67 PI assessment of NETs. In the future, this approach could be useful in, for example, multi‐center clinical trials where objective estimation of Ki‐67 PI is crucial.

16 January 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
TVTiina Vesterinen
Tiina Vesterinen
HLHelena Leijon
Helena Leijon
HMHarri Mustonen
Harri Mustonen
SRSatu Remes
Satu Remes
AKAija Knuuttila
Aija Knuuttila
CHCaj Haglund
Caj Haglund
Context Pulmonary carcinoids (PC) belong to neuroendocrine tumors that often overexpress somatostatin receptors (SSTR). This overexpression provides a molecular basis for tumor imaging and treatment with somatostatin analogs. Objective To evaluate SSTR1–5 distribution in a large set of PC tumors and to investigate whether the expression is associated with clinicopathological and outcome data. Design, setting and patients This retrospective study was conducted at Helsinki University Hospital and University of Helsinki. It included 178 PC tumors coupled with patients’ clinical data retrieved through Finnish biobanks. After histological re-classification, tissue specimens were processed into next-generation tissue microarray format and stained immunohistochemically with novel monoclonal SSTR1-5 antibodies. Main outcome measure SSTR1-5 expression in PC tumors. Results Expression of SSTR1–5 was detected in 52%, 75%, 56%, 16%, and 32% of the tumors, respectively. Membrane-bound staining was observed for all receptors. SSTR2 negativity and SSTR4 positivity was associated with lymph node involvement at the time of surgery (P=0.014 and P=0.017, respectively) and with distant metastasis (P=0.027 and P=0.015, respectively). SSTR3 and SSTR4 expression was associated with increased risk of shorter survival (P=0.046, HR 4.703, 95% CI 1.027-21.533 and P=0.013, HR 6.64, 95% CI 1.48-29.64, respectively) while expression of SSTR1 and SSTR2 was associated with improved outcome (P=0.021, HR 0.167, 95% CI 0.037–0.765 and P=0.022, HR 0.08, 95% CI 0.01-0.70, respectively). Conclusion SSTR1–5 expression is observed in pulmonary carcinoids. As SSTR expression is associated with the tumor’s metastatic potential and patient outcome, these receptors may offer the possibility for individualized prognosis estimation.

31 July 2010 in Oral Oncology
Verified
Journal Article
Closed access
PPPratikshya Pradhan-Palikhe
Pratikshya Pradhan-Palikhe
TVTiina Vesterinen
Tiina Vesterinen
JTJussi Tarkkanen
Jussi Tarkkanen
ILIlmo Leivo
Ilmo Leivo
TSTimo Sorsa
Timo Sorsa
PMPetri S. Mattila
Petri S. Mattila

20 February 2018 in Acta Oncologica
Verified
Journal Article
Open access
TVTiina Vesterinen
Tiina Vesterinen
SMSanna Mononen
Sanna Mononen
KSKaisa Salmenkivi
Kaisa Salmenkivi
HMHarri Mustonen
Harri Mustonen
JRJari Räsänen
Jari Räsänen
JAJohanna T. Arola
Johanna T. Arola
Background: Pulmonary carcinoids (PC) are rare malignant neoplasms that cover approximately 1% of all lung cancers. PCs are classified by histological criteria as either typical (TC) or atypical (AC). Histological subtype is the most studied prognostic factor. The aim of this study was to evaluate if other tissue or clinical features are associated with patient outcomes. Material and methods: We retrospectively reviewed clinical records of 133 PC patients who underwent operation in the Helsinki University Hospital between 1990 and 2013. Tissue specimens were re-evaluated, processed into tissue microarray format and stained immunohistochemically with serotonin, calcitonin, adrenocorticotropic hormone (ACTH), thyroid transcription factor-1 (TTF-1) and Ki-67. Survival and risk analyses were performed. Results: Based on histology, 75% (n = 100) of the tumors were TCs and 25% (n = 33) ACs. TCs had higher 10-year disease-specific survival (DSS) rate than ACs (99% (95% CI, 93–100%) for TCs vs. 82% (95% CI, 61–92%) for ACs). Hormonally active tumors expressing serotonin, calcitonin or ACTH were noted in 53% of the specimens but hormonal expression was not associated with DSS. TTF-1 was positive in 78% of the specimens but was not associated with DSS. Ki-67 index varied between <1% and 15%. Ki-67 ≥ 2.5% was associated with shorter DSS (p = .004). The presence of metastatic disease (p = .001), tumor size ≥30 mm (p = .021) and atypical histology (p = .011) were also associated with disease-specific mortality. Conclusions: We conclude that PCs are uncommon tumors. When resected, the long-term survival is in general favorable. In this consecutive, single-institution cohort of patients, presence of metastatic disease, tumor size, histological subtype and Ki-67 index were associated with shorter disease-specific survival. As TC and AC have different clinical behaviors, the correct tumor classification at the time of diagnosis is a necessity.